Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. director Kathryn E. Wengel increased her direct common stock holdings through equity compensation. On February 11, 2026, 897 Restricted Stock Units were exercised for 897 shares of Labcorp common stock at an exercise price of $0 per share.
After this conversion, Wengel directly owned 4,133 shares of Labcorp common stock. She also held 773 Restricted Stock Units as of that date, with each unit representing the contingent right to receive one share of Labcorp common stock upon vesting.
Labcorp Holdings Inc. director Richelle P. Parham acquired 897 shares of common stock on February 11, 2026 through the exercise and conversion of restricted stock units (RSUs) at $0 per share. This reflects equity compensation vesting rather than an open‑market purchase.
Following the transaction, Parham directly owns 3,366 shares of Labcorp common stock and holds 773 restricted stock units, each representing the contingent right to receive one share of common stock when they vest.
Labcorp Holdings Inc. director Peter M. Neupert reported the vesting and exercise of equity awards. On February 11, 2026, he exercised 897 Restricted Stock Units, converting them into 897 shares of Common Stock at an exercise price of $0 per share. Following this derivative conversion, he directly owned 13,784 shares of Common Stock and 773 Restricted Stock Units, each RSU representing the right to receive one Labcorp common share.
Labcorp Holdings director Garheng Kong reported acquiring shares through the vesting and conversion of restricted stock units. On February 11, 2026, 897 Restricted Stock Units converted into 897 shares of common stock at an exercise price of $0 per share.
Each Restricted Stock Unit represents the right to receive one Labcorp common share. After this transaction, Kong directly holds 13,739 shares of common stock and 773 Restricted Stock Units, which reflects the remaining aggregate RSU balance.
Labcorp Holdings Inc. director Kirsten Marie Kliphouse reported acquiring 897 shares of common stock through the vesting and conversion of restricted stock units. The RSUs fully vested on February 11, 2026, and after the transaction she directly holds 3,160 Labcorp common shares and 773 restricted stock units.
Labcorp Holdings Inc. director Jeffrey A. Davis acquired common shares through equity compensation. On February 11, 2026, 897 Restricted Stock Units were exercised/converted at $0 into 897 shares of Labcorp common stock. After this transaction, Davis directly held 5,460 common shares and 773 Restricted Stock Units.
Labcorp Holdings Inc. director Kerrii B. Anderson reported the vesting and exercise of 897 Restricted Stock Units on February 11, 2026, converting them into an equal number of Labcorp common shares at $0 per share. Following this derivative conversion, she directly holds 9,563 common shares and 773 remaining Restricted Stock Units, plus indirect holdings of 144 common shares in each of two separate trusts.
Labcorp Holdings Inc. reported that its President, CEO and director Adam H. Schechter received new equity awards on February 10, 2026. He was granted 31,700 non-qualified stock options with a $284.50 exercise price, vesting in three equal annual installments and expiring in 2036.
He also received 10,440 Restricted Stock Units (RSUs), each representing one share of Labcorp common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this grant, he holds an aggregate of 25,870 RSUs.
Labcorp Holdings Inc. executive Jonathan C. Meltzer reported multiple equity transactions. On February 10, 2026, he sold 91 shares of Labcorp common stock in an open-market transaction at $276.79 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 2,696.3256 shares held directly.
On the same date, he was granted 1,900 non-qualified stock options with an exercise price of $284.50, vesting in three equal annual installments starting February 10, 2027 and expiring on February 9, 2036. He also received 620 restricted stock units, which vest in three equal annual installments beginning February 10, 2027, bringing his directly held RSUs to 2,937 units, each representing one share of Labcorp common stock.
Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported new equity awards. On February 10, 2026, she received 2,700 non-qualified stock options with an exercise price of $284.5 per share, granted under the Labcorp 2025 Omnibus Incentive Plan. These options vest in three equal annual installments starting on the grant date and are exercisable until February 9, 2036.
She was also granted 880 Restricted Stock Units (RSUs), each representing one share of common stock. The RSUs vest in three equal annual installments beginning on February 10, 2027. After this grant, she holds a total of 2,480 RSUs directly.